Cargando…
Pediococcus acidilactici CECT9879 (pA1c) Counteracts the Effect of a High-Glucose Exposure in C. elegans by Affecting the Insulin Signaling Pathway (IIS)
The increasing prevalence of metabolic syndrome-related diseases, including type-2 diabetes and obesity, makes it urgent to develop new alternative therapies, such as probiotics. In this study, we have used Caenorhabditis elegans under a high-glucose condition as a model to examine the potential pro...
Autores principales: | Yavorov-Dayliev, Deyan, Milagro, Fermín I., Ayo, Josune, Oneca, María, Aranaz, Paula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910957/ https://www.ncbi.nlm.nih.gov/pubmed/35269839 http://dx.doi.org/10.3390/ijms23052689 |
Ejemplares similares
-
Glucose-lowering effects of a synbiotic combination containing Pediococcus acidilactici in C. elegans and mice
por: Yavorov-Dayliev, Deyan, et al.
Publicado: (2023) -
Antidiabetic Effects of Pediococcus acidilactici pA1c on HFD-Induced Mice
por: Cabello-Olmo, Miriam, et al.
Publicado: (2022) -
Pediococcus acidilactici pA1c(®) Improves the Beneficial Effects of Metformin Treatment in Type 2 Diabetes by Controlling Glycaemia and Modulating Intestinal Microbiota
por: Cabello-Olmo, Miriam, et al.
Publicado: (2023) -
Recombinant laccase from Pediococcus acidilactici CECT 5930 with ability to degrade tyramine
por: Callejón, Sara, et al.
Publicado: (2017) -
Anti-Obesity Efficacy of Pediococcus acidilactici MNL5 in Canorhabditis elegans Gut Model
por: Barathikannan, Kaliyan, et al.
Publicado: (2022)